Ella Instrument- Automated Immunoassay Machine acquisition

The National Institutes of Health, specifically the National Institute of Neurological Disorders and Stroke (NINDS) Translational Neuroradiology Section, requires the acquisition of an Ella Automated Immunoassay Machine. This system is necessary to support ongoing investigations into the mechanisms by which multiple sclerosis and related neuroinflammatory pathologies impact the central nervous system. The equipment provides high-throughput, high-sensitivity multiplexed protein analysis of serum and plasma samples, specifically for quantifying biomarkers such as neurofilament light chain and glial fibrillary acidic protein. This requirement is categorized under NAICS code 334516 for Analytical Laboratory Instrument Manufacturing and PSC code 6640 for Laboratory Equipment and Supplies.

The acquisition is managed by the National Institutes of Health OLAO with a primary place of performance in Bethesda, Maryland. This pre-solicitation notice, identified by solicitation number 75N98026Q00510, does not include a set-aside designation. Interested parties must submit responses by the deadline of June 8, 2026. Vishnuvajjala Hanumanth Rao serves as the point of contact for this requirement, which includes one attachment titled index.pdf.

Access to the Ella Immunoassay System platform is essential for the NINDS to maintain the rigor and reproducibility required for translational neuroimmunology studies. The system is utilized for its rapid turnaround, platform stability, and minimal sample volume requirements. By enabling the precise quantification of critical indicators of axonal damage and astrocyte activation, the instrument supports the agency’s mission to conduct high-impact central nervous system research and comprehensive immune profiling.